The biological target of the study is totipotency, the remarkable capacity of a cell to give rise to every tissue in the body, including both the embryo proper and the extraembryonic structures such as the placenta that are essential for a viable pregnancy. In mammals, true totipotency is fleeting. In humans it exists only during the earliest cleavage divisions after fertilization, and the moment of greatest importance arrives at the eight-cell stage, when the embryonic genome is largely switched on in a process known as zygotic genome activation. Because human embryos at this stage are scarce, protected by strict ethical and legal restrictions, researchers have sought ways to recreate eight-cell-like states in culture dishes using stem cells as raw material.

Previous efforts to generate such eight-cell-like cells, abbreviated 8CLCs, have taken several routes. One influential strategy used transient overexpression of DUX4, a transcription factor normally activated at the eight-cell stage, to nudge pluripotent cells toward a totipotent-like identity. Others relied on multistep chemical treatments, including a four-chemical cocktail with leukemia inhibitory factor known as 4CL, or on inhibiting the spliceosome, the cellular machinery that processes RNA, to produce totipotent blastomere-like cells in human and cynomolgus monkey cells. Each approach advanced the field, but all carried drawbacks that limited their usefulness.

The limitations were substantial. The 4CL protocol demanded nearly three weeks of continuous induction and yielded only around 10 percent of cells expressing TPRX1, a key marker of the eight-cell state. Spliceosomal inhibition, while enabling impressive functional evidence of totipotency-like behavior, produced populations whose efficiency and frequency were not fully characterized. Perhaps most fundamentally, many of these strategies judged success by a single marker such as TPRX1, which the authors argue cannot fully resolve whether the induced cells genuinely match the molecular fingerprint of natural eight-cell blastomeres or merely superficially resemble them.

To overcome these obstacles, the team, led by Xi Kong, Nan Jiang, Shaowei Chen and Xingyou Zhang under the supervision of Huangfan Xie and Bingqing Xie at Southwest Medical University and collaborating institutions in Sichuan, engineered a human pluripotent stem cell line carrying two fluorescent reporters. One reporter drives green fluorescent protein from the TPRX1 locus, the other drives a red fluorescent protein from ZSCAN4, another gene associated with early cleavage-stage embryos. This dual-reporter system allowed the researchers to watch, in real time and at single-cell resolution, exactly which cells converted and to isolate the double-positive population for deep molecular analysis.

With this tool in hand, the researchers performed systematic chemical screening to identify a combination capable of driving conversion efficiently. The resulting cocktail, 7CL, comprises seven small molecules together with leukemia inhibitory factor. Within just six days of treatment, roughly 51.5 percent of the cells expressed TPRX1, a fivefold improvement in yield over the earlier four-chemical protocol and a dramatic reduction in induction time from about twenty days to under a week. The speed and efficiency matter practically: shorter protocols reduce the opportunity for unwanted genetic and epigenetic damage to accumulate, and higher yields make downstream analyses and applications far more feasible.

Crucially, the team found that within the TPRX1-positive population there existed a transcriptionally refined subpopulation that also expressed ZSCAN4. When the researchers compared this double-positive population to genuine human eight-cell blastomeres using transcriptomic and epigenomic profiling, the correspondence was striking. The induced cells faithfully recapitulated both the gene-expression patterns and the chromatin-level features of their natural counterparts, suggesting that the 7CL protocol does not merely flip a marker gene but genuinely reconfigures the cellular regulatory landscape toward an eight-cell identity. Single-cell analyses, in which the gene activity of thousands of individual cells is charted, supported this conclusion by revealing a trajectory from primed pluripotency through intermediate states into a coherent eight-cell-like program.

The functional evidence is what elevates the work beyond molecular mimicry. When tested in vitro, the 7CL-induced cells showed the capacity to contribute to both embryonic and extraembryonic lineages, the defining functional property that distinguishes totipotent cells from the merely pluripotent stem cells from which they were derived. The authors also report in vivo contribution experiments, in which the induced cells were assessed for their ability to participate in tissue formation in living systems. Together these assays provide the kind of evidence that the totipotency field has increasingly demanded: not just the presence of eight-cell markers, but the demonstrated developmental plasticity that those markers are supposed to signify.

The implications reach across several domains of biology and medicine. A robust, chemically defined, six-day protocol for generating faithful eight-cell-like cells provides an unprecedented platform for studying zygotic genome activation, a process whose misregulation is thought to underlie some cases of early embryonic loss and infertility. Because the cells are generated without genetic manipulation of the type required for DUX4 overexpression, the protocol reduces concerns about genome alteration and offers a more translatable route. Large numbers of eight-cell-like cells could also serve as models for drug and toxin screening during the earliest window of embryonic development, a period that has been almost entirely inaccessible to direct experimentation in humans.

The study also refines the methodological standards of the field. By combining a dual-reporter system with transcriptomic and epigenomic validation, and by reporting yields explicitly rather than leaving efficiency ambiguous, the researchers offer a template for how totipotency-like states should be defined and verified. Challenges remain, including the incomplete characterization that still shadows some alternative approaches, the need to confirm the full developmental potential of induced populations, and the ethical questions that inevitably accompany any advance in engineering embryo-like cells. The work was supported by the National Natural Science Foundation of China and Sichuan provincial programs, and the authors report no competing interests. As chemical reprogramming continues to mature, the ability to rewind a mature stem cell to the earliest recognizable stage of human development promises to make one of biology’s most guarded secrets at least partially legible in a laboratory dish.

Subject of Research: Chemical induction of 8-cell-like totipotent states in human pluripotent stem cells

Article Title: Chemical reprogramming of human pluripotent stem cells into 8-cell-like states

Article References: Kong, X., Jiang, N., Chen, S., Zhang, X., Huang, A., Yi, S., Zhang, J., Yin, S., Peng, J., Jiang, Y., Xie, H., & Xie, B. (2026). Chemical reprogramming of human pluripotent stem cells into 8-cell-like states. Cell Research. https://doi.org/10.1038/s41422-026-01314-9

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01314-9

Keywords: totipotency, human pluripotent stem cells, 8-cell-like cells, chemical reprogramming, zygotic genome activation, TPRX1, ZSCAN4, Cell Research, embryo model, stem cells, epigenomics, cell fate

The logic behind the approach rests on a simple biological premise. Thyroid follicular cells do not merely produce thyroxine and triiodothyronine; they also metabolize these hormones through a network of deiodinases, sulfotransferases, glucuronidation pathways and other enzymatic steps. Cancerous transformation rewrites cellular metabolism wholesale, and there is no reason to expect that the handling of thyroid hormones would be spared. If malignant nodules process thyroid hormone differently from benign ones, the downstream metabolites released into the bloodstream should carry a detectable signature. The researchers set out to test whether that signature could be captured with liquid chromatography–mass spectrometry, a technique sensitive enough to quantify trace metabolites in serum with high precision.

To appreciate why such a test is needed, it helps to review how thyroid nodules are evaluated today. The diagnostic pathway typically begins with neck ultrasonography, interpreted through the American College of Radiology’s Thyroid Imaging Reporting and Data System, known as ACR TI-RADS. This system assigns nodules to one of five incremental categories, from 1 to 5, with categories 1 and 2 indicating benign or non-suspicious findings and category 5 flagging nodules that are highly suspicious for malignancy. Sonography is cheap, noninvasive and widely available, but it is anatomic rather than molecular: it describes what a nodule looks like, not what it is. Overlapping features between benign and malignant lesions mean that many nodules land in an uncertain middle ground.

The second pillar of diagnosis is fine-needle aspiration biopsy, in which cells are drawn from the nodule and examined under a microscope. Results are reported through the Bethesda System for Reporting Thyroid Cytopathology, or TBSRTC, which comprises six diagnostic categories, each tied to an estimated risk of malignancy. Category I is non-diagnostic, category II is benign, category III is atypia of undetermined significance, category IV is follicular neoplasm, category V is suspicious for malignancy and category VI is malignant. For patients in categories V and VI, surgery is usually straightforward. The trouble lies in categories III and IV — the cytologically indeterminate nodules that account for 25 to 30 percent of biopsy results and pose what the authors describe as a major diagnostic challenge in current thyroid nodule management.

Indeterminate nodules create a cascade of clinical anxiety and overtreatment. Because cytology cannot reliably distinguish a benign follicular lesion from a follicular carcinoma, many patients with Bethesda III or IV results undergo diagnostic surgery — a hemithyroidectomy performed largely to obtain a definitive histopathological answer. The majority of those operations, by most estimates, remove nodules that turn out to be benign. Each unnecessary surgery carries real costs: general anesthesia, a scar on the neck, a small risk of injury to the recurrent laryngeal nerve or the parathyroid glands, and, for some patients, lifelong thyroid hormone replacement. Molecular tests performed on biopsy material have improved triage in recent years, but they require adequate cellular material, add expense, and still leave a residue of uncertainty. A test that works on serum — a simple blood draw independent of the biopsy — would sidestep several of these limitations at once.

That is precisely the niche the THM test is designed to occupy. The study, registered in the Chinese Clinical Trial Registry under identifier ChiCTR2300070912 and approved by the ethics committees of participating centers including Xuzhou Central Hospital, Liyang People’s Hospital, the First Affiliated Hospital of Anhui Medical University, Fudan University Cancer Center and Shandong First Medical University Affiliated Endocrine and Metabolic Disease Hospital, enrolled patients with thyroid nodules across multiple hospitals in China. All participants provided informed consent. Serum samples were collected before surgical pathology was known, and the concentrations of thyroid hormone metabolites were measured by liquid chromatography coupled to tandem mass spectrometry, a gold-standard analytical platform for targeted metabolomics.

The analytical workflow matters as much as the biology. Targeted metabolomics of thyroid hormones and their derivatives is technically demanding because these iodinated compounds exist at very low concentrations in blood, bind to carrier proteins, and are chemically similar to one another. The research team, with Guo, Zang, Zou and Peng performing the LC-MS analysis, had to resolve closely related molecular species — the various deiodinated, sulfated and conjugated forms of T4 and T3 — and quantify them reproducibly across hundreds of clinical samples. Data analysis, led by Guo, Sun and Liu, then searched for metabolite patterns that separated malignant from benign nodules, ultimately distilling the measurements into a diagnostic test intended to complement, rather than replace, existing tools.

The clinical vision that emerges from the paper is a layered diagnostic algorithm. Ultrasonography would continue to serve as the first filter, identifying nodules that warrant biopsy. Fine-needle aspiration would continue to provide cytology, and for the substantial fraction of results that fall into Bethesda categories III and IV, the serum THM test would offer an additional, independent line of molecular evidence drawn from the patient’s blood. Because the test interrogates systemic hormone metabolism rather than a handful of cells on a slide, it captures tumor biology that cytology and even many DNA- and RNA-based molecular panels do not directly measure. The authors frame the test as a tool for the molecular diagnostic evaluation of thyroid nodules — a way to convert an indeterminate cytology result into a more confident decision about whether surgery is truly necessary.

Several features of the study strengthen its credibility. The work was a multi-center collaboration spanning endocrinology, thyroid surgery, head and neck surgery, ultrasound and pharmacy departments, with sample collection performed by Geng, Wan, Zhou, Song, Liao and Xi across hospitals in Jiangsu, Anhui, Shanghai and Shandong provinces. The study was conceived and supervised by Liang, Xing and Wang, and the manuscript was drafted by Guo and Geng with editing from Liang and Xing. The authors declare no competing interests, and the work received support from the National Natural Science Foundation of China, the Natural Science Foundation of Jiangsu Province, the Science and Technology Commission of Shanghai Municipality and several regional programs. The publication appears as a letter to the editor in Cell Research, a format that typically presents a focused, complete finding rather than an exhaustive monograph, and the published figure summarizes the study design and the test’s performance in the differential diagnosis of thyroid nodules.

The broader significance of this work extends beyond the thyroid. Metabolomics is increasingly recognized as a rich source of liquid-biopsy information, complementing the circulating DNA and RNA markers that have dominated the molecular diagnostics conversation. Thyroid hormone metabolites offer a uniquely attractive analyte class for thyroid nodules because they are organ-specific by definition: only thyroid tissue makes thyroid hormones, so changes in their metabolic profile point directly to perturbations in thyroid physiology. If the THM test’s performance holds up in independent cohorts and in routine clinical use, patients facing the most common and most frustrating biopsy result in thyroid medicine — an indeterminate nodule — could one day get a clearer answer from a vial of blood, sparing many of them an operation they never needed. For a disease detected in nodules found in up to seventy percent of adults, that would be no small thing.

Subject of Research: A serum thyroid hormone metabolite test for molecular diagnostic evaluation of thyroid nodules

Article Title: A serum thyroid hormone metabolite test for molecular diagnostic evaluation of thyroid nodules

Article References: Guo, M., Geng, H., Sun, Q., Wan, H., Zhou, P., Song, Y., Zou, C., Zang, X., Xi, H., Liao, T., Liu, X., Peng, G., Wang, Y., Xing, M., Liang, J., for the “THMs Group”, Liang, J., Geng, H., Liu, X., … Zhou, P. (2026). A serum thyroid hormone metabolite test for molecular diagnostic evaluation of thyroid nodules. Cell Research. https://doi.org/10.1038/s41422-026-01300-1

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01300-1

Keywords: thyroid nodules, thyroid cancer, thyroid hormone metabolites, metabolomics, liquid biopsy, fine-needle aspiration biopsy, Bethesda System, ACR TI-RADS, molecular diagnostics, LC-MS, differentiated thyroid cancer, Cell Research

The enzyme in question is RNASET2, a ribonuclease best known for its role in antimicrobial defense. It chops up RNA derived from pathogens into small fragments that are subsequently detected by Toll-like receptors 7 and 8, sensors that help ignite innate immune responses. The clinical importance of this protein is underscored by a rare human condition: children born without functional RNASET2 develop cystic leukoencephalopathy, a brain disorder accompanied by elevated inflammatory markers in the cerebrospinal fluid and peripheral blood. Mice engineered to lack RNASET2 show a similar picture, with heightened expression of interferon-stimulated genes and neuroinflammation. All of this suggested that RNASET2 acts as a brake on innate immunity.

That brake, the Xiamen team reasoned, might be exactly what cancer cells exploit. Tumors routinely dampen innate immune signaling within themselves as a way of escaping immune surveillance, and any machinery that clears away danger signals could serve that purpose. The researchers therefore set out to determine whether RNASET2 contributes to this immune evasion, and whether releasing the brake could restore the tumor’s visibility to the immune system.

The danger signal RNASET2 clears is double-stranded RNA arising from the cell’s own genome. Mitochondria, the energy-producing organelles descended from ancient bacteria, continually transcribe their compact genomes, and the resulting mitochondrial double-stranded RNA can spill into the surrounding cytoplasm. Work over the past decade has established that this mitochondrial RNA is a potent trigger of innate immune pathways, and that cells must actively manage it to avoid chronic inflammation. RNASET2, the new study shows, is one of the managers: it degrades mitochondrial double-stranded RNA before it can accumulate and provoke a response.

The most striking twist in the study is chemical. RNASET2’s RNA-destroying activity is sensitive to magnesium, the abundant biological cation that sits at the heart of many enzymatic reactions. The researchers found that magnesium modulates the enzyme’s ability to clear double-stranded RNA, and that enhancing magnesium effectively inhibits RNASET2 function in this context. When RNASET2 is inhibited, mitochondrial double-stranded RNA builds up inside tumor cells, and that accumulation is not silent. The accumulating RNA trips innate immune sensors, driving the production of interferons and other inflammatory mediators that convert an immunologically cold tumor into an inflamed one.

That inflammatory conversion has direct consequences for therapy. Checkpoint inhibitors such as antibodies targeting PD-1 and PD-L1 work by releasing T cells from inhibition, but they depend on the tumor already being recognized as foreign. Tumors with high baseline innate immune signaling, often described as inflamed or hot tumors, respond far better than cold tumors that present no danger signals for T cells to act on. By forcing the accumulation of mitochondrial double-stranded RNA, RNASET2 inhibition manufactures exactly the inflammatory context that checkpoint blockade needs, and the study demonstrates that combining the two approaches boosts antitumor immunity in preclinical models.

The findings also reframe a familiar nutrient in a new light. Magnesium has long been appreciated as essential for T cell function; earlier work published in Cell in 2022 showed that magnesium is required for the proper function of cytotoxic T cells and that low magnesium environments impair their ability to kill infected or malignant cells. The new study adds a second, complementary mechanism: magnesium also shapes the innate immune landscape of the tumor itself by regulating an RNA clearance enzyme. A single ion thus influences both the effector arm of the immune response and the alarm signals that summon it, a convergence that may help explain why magnesium status correlates with cancer outcomes in epidemiological studies.

For the researchers, the path from basic enzymology to therapeutic strategy ran through a paradox. RNASET2 is, on balance, an anti-inflammatory protein, and one might expect that removing it would simply cause indiscriminate inflammation with little therapeutic benefit. Instead, the study shows that the inflammation generated by stalled RNA clearance is precisely targeted at the tumor, because it is the tumor’s own mitochondrial RNA that accumulates. This makes the intervention conceptually similar to other strategies that deliberately unleash self-derived nucleic acid sensing, such as inhibitors of TREX1 or STING agonists, but with a distinct molecular entry point and a simple dietary or pharmacological lever in the form of magnesium.

Considerable work remains before the approach could reach patients. The study is grounded in mouse models and mechanistic cell biology, and the therapeutic window will need careful definition: RNASET2 deficiency in humans causes a serious neuroinflammatory disease, so any clinical strategy must elevate RNA accumulation within tumors without reproducing systemic pathology. It is also not yet clear which tumor types, which dosing regimens of magnesium or RNASET2 inhibitors, and which combinations with existing immunotherapies would be optimal. The authors declare no competing interests, and the work was supported by the National Natural Science Foundation of China and related national programs, reflecting a sustained public investment in innate immunity research.

Even so, the study offers a memorable conceptual advance: the immune system’s alarm bells are not only rung and heard but actively muffled, and the muffling machinery can be switched off. If RNASET2 inhibition or magnesium-based approaches can be translated safely, a routine mineral could become an unlikely partner for the most sophisticated cancer drugs on the market, turning cold tumors hot by simply refusing to let them take out the trash.

Subject of Research: RNASET2-mediated clearance of mitochondrial double-stranded RNA and its inhibition to enhance cancer immunotherapy

Article Title: Inhibition of a magnesium-sensitive double-stranded RNA clearance machinery boosts cancer immunotherapy

Article References: Zhang, Z., Zhang, L., Luo, H., Huo, Y., Sun, B., Shi, J., Wu, S., Wang, P., & Wang, G. (2026). Inhibition of a magnesium-sensitive double-stranded RNA clearance machinery boosts cancer immunotherapy. Cell Research. https://doi.org/10.1038/s41422-026-01301-0

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01301-0

Keywords: RNASET2, mitochondrial double-stranded RNA, cancer immunotherapy, innate immunity, magnesium, tumor immune evasion, interferon signaling, Toll-like receptors, checkpoint inhibitors, ribonuclease, tumor microenvironment, Cell Research

Splicing is the molecular editing step that removes non-coding introns from freshly made RNA transcripts and joins the protein-coding exons together. The machinery responsible, the spliceosome, must identify precise boundaries between exons and introns, most critically the 3′ splice site that marks the end of an intron. In most human genes, this task is made easier by the underlying nucleotide composition: exons tend to be rich in guanine and cytosine, the G and C of the DNA alphabet, while the surrounding introns are rich in adenine and thymine. That contrast gives the splicing machinery a clear signal of where exons begin and end. But a distinct subset of genes breaks this rule. In these genes, both exons and introns are GC-rich, producing a GC-leveled architecture in which the usual compositional contrast between coding and non-coding regions largely disappears.

That architectural quirk has consequences. When exons and introns carry similar GC content, the spliceosome loses one of its strongest clues for distinguishing exon from intron, and the 3′ splice sites in these genes tend to be cytosine-rich and depleted of thymine, features that make them intrinsically weak substrates for recognition by the splicing machinery. The new study set out to determine how cells manage to splice these difficult genes efficiently despite their unfavorable sequence landscape. The answer, the researchers report, lies in a compartment that has fascinated cell biologists for decades: the nuclear speckle.

Nuclear speckles are membraneless organelles, dense droplet-like structures within the nucleus that are packed with RNA-processing factors, including many components of the spliceosome. Rather than being passive storage depots, speckles are now understood to function as dynamic hubs for RNA metabolism, exchanging factors with nearby genes and concentrating the molecular tools needed for transcript maturation. Recent work has shown that speckles are largely organized by two large scaffold proteins, SON and SRRM2, and that genes located in close spatial proximity to speckles tend to be spliced more efficiently than genes farther away. What remained unclear was the molecular mechanism connecting that spatial coupling to the actual chemistry of splicing.

The Zhejiang University team, led by corresponding author Yafei Yin with important contributions from Xiaoyu Li, approached the question by combining acute protein depletion with a battery of genome-wide assays. Using the dTAG degron system, a technique that allows rapid and targeted destruction of a chosen protein inside living cells, the researchers generated cell lines in which SON could be eliminated on demand. They then profiled the consequences using 4sU-seq, which captures newly synthesized RNA and therefore reports directly on splicing efficiency in real time, along with CLIP-seq and TurboRIP-seq to map where SON binds and which RNA-protein complexes it associates with, U2 RAP-seq to follow the recruitment of the U2 spliceosomal component to pre-messenger RNA, and Pol II ChIP-seq to track the behavior of the RNA polymerase II enzyme that transcribes genes into RNA. All of the resulting datasets have been deposited in the NCBI Gene Expression Omnibus under accession number GSE325871, allowing other researchers to examine the raw evidence.

The data converged on a clear conclusion. When SON was removed, splicing defects appeared preferentially in GC-rich genes, precisely the subset whose weak, cytosine-rich and thymine-poor 3′ splice sites make them dependent on extra help. The mechanism the authors propose is that SON stabilizes the recognition of those weak splice sites, effectively propping up the first and most error-prone step of spliceosome assembly at GC-rich intron boundaries. In other words, SON does not change the sequence of the gene, but it changes the probability that the splicing machinery correctly interprets a difficult sequence, converting what would otherwise be inefficient and error-prone processing into fast, accurate exon joining.

This mechanism elegantly explains why GC-leveled genes cluster near nuclear speckles in the first place. If a gene’s splice sites are inherently weak, the gene benefits from sitting close to a reservoir of concentrated splicing factors, and SON, as a core scaffold of the speckle, appears to be the factor that translates physical proximity into biochemical support. The finding also assigns a concrete molecular role to SON that goes beyond its established architectural function in organizing speckle structure alongside SRRM2. SON, the study suggests, is not merely a beam holding the nuclear compartment together; it is an active participant in the splicing reactions that the compartment enables.

The implications reach beyond basic cell biology. SON has previously been implicated in human disease, and genes with GC-rich, GC-leveled architecture include many regulators of development and cell growth, so understanding how their splicing is safeguarded could illuminate why nuclear organization fails in certain disorders. The work also connects to a broader theme in modern biology: the recognition that genome function depends on spatial organization, with the position of a gene relative to nuclear bodies influencing how efficiently it is expressed. By identifying the sequence feature, the weak 3′ splice site, that makes a gene dependent on speckle proximity, the study provides a concrete molecular bridge between nuclear geography and RNA chemistry, a bridge that has been hypothesized but never resolved in such detail.

Technically, the study stands out for its use of complementary high-throughput methods applied after acute, rather than chronic, protein loss. Chronic depletion experiments can be confounded by secondary effects as cells adapt over days, whereas the dTAG system destroys SON within hours, allowing the researchers to observe the primary consequences of its absence. The combination of nascent RNA sequencing with crosslinking-based binding maps and polymerase occupancy data allowed the team to distinguish direct effects on splice-site recognition from indirect effects on transcription or RNA stability, strengthening the causal chain from SON binding to efficient splicing of GC-rich transcripts.

Open questions remain. The precise molecular contacts through which SON stabilizes 3′ splice-site recognition, whether through direct binding to the weak cytosine-rich sites, through recruitment of U2 snRNP components, or through both routes acting in concert, will require structural and biochemical follow-up. It also remains to be seen whether other speckle components, including the co-scaffold SRRM2, contribute redundant or specialized support for different classes of weak splice sites. Nevertheless, by demonstrating that a single nuclear speckle protein safeguards the splicing of an entire architectural class of genes, the study transforms nuclear speckles from a correlated curiosity into a mechanistically understood support system, and it gives researchers a new lens for examining how the architecture of the genome and the architecture of the nucleus co-evolved to make complex gene expression possible.

Subject of Research: Role of the nuclear speckle protein SON in the splicing of GC-rich genes

Article Title: Nuclear speckle protein SON safeguards efficient splicing of GC-rich genes

Article References: Fan, W., Zhou, Y., Zhang, X., Tong, C., Li, X., & Yin, Y. (2026). Nuclear speckle protein SON safeguards efficient splicing of GC-rich genes. Cell Research. https://doi.org/10.1038/s41422-026-01303-y

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01303-y

Keywords: nuclear speckles, SON, RNA splicing, GC-rich genes, spliceosome, 3′ splice site, dTAG degron, 4sU-seq, CLIP-seq, nuclear organization, pre-mRNA processing, Cell Research

Gasdermins occupy a unique position in the architecture of innate immunity. The family, which in humans includes GSDMA, GSDMB, GSDMC, GSDMD and GSDME, shares a common operational logic. Each protein consists of a cytotoxic N-terminal domain tethered to a C-terminal domain that acts as an internal restraint. In the resting state, the two domains bind each other so that the pore-forming capacity of the N-terminus is masked. When pattern-recognition receptors detect pathogen-associated or damage-associated molecular patterns, they trigger proteolytic cascades—inflammasome assemblies that activate inflammatory caspases such as caspase-1, caspase-4, caspase-5 and caspase-11, and, in apoptotic contexts, caspase-3 or granzyme-mediated cleavage. These enzymes cut the gasdermin at a flexible linker region, releasing the N-terminal fragment. Freed from its autoinhibitory partner, the fragment translocates to the plasma membrane, oligomerizes and inserts a large beta-barrel pore with an inner diameter on the order of 10 to 20 nanometers.

The consequences of pore formation are dramatic and rapid. Ions rush down their electrochemical gradients, water follows osmotically, the cell swells and bursts in the lytic mode of death known as pyroptosis. Before rupture, the pores permit the efflux of potassium and the release of mature interleukin-1beta and interleukin-18, alarmins such as high-mobility group box 1, and other inflammatory cargo that summon and shape the immune response. Pyroptosis is therefore not merely a demolition but a broadcast: the dying cell converts its own destruction into an alarm signal that recruits neutrophils, activates antigen-presenting cells and biases the adaptive immune system toward antiviral effector programs. This dual character—killing and alerting—makes the gasdermin system attractive for therapeutic exploitation, particularly against pathogens that thrive by suppressing or evading conventional immune pathways.

Viruses and gasdermins have long been adversaries in an evolutionary arms race. Many viruses encode inhibitors that block inflammasome sensors, sequester gasdermin fragments or interfere with caspase activation, reflecting the selective pressure that pyroptosis exerts on viral replication. Poxviruses, herpesviruses, influenza viruses and coronaviruses all deploy strategies to dampen inflammatory cell death. Conversely, host cells can route viral sensing signals toward gasdermin activation through multiple sensors, including ZBP1, which detects influenza A virus through recognition of Z-form nucleic acid, and AIM2 or IFI16, which sense foreign DNA. The observation that gasdermin activation can restrict viral replication even when interferon responses are disabled underscores the pathway’s value as a fail-safe. The Cell Research article situates the new engineering efforts within this biological context, arguing that the natural system’s potency has been limited chiefly by its lack of specificity and by viral countermeasures.

Here artificial intelligence changes the calculus. Modern structure-prediction systems such as AlphaFold2 and its successors have resolved the atomic architectures of gasdermin domains, their autoinhibited complexes and their membrane-inserted oligomeric pores, giving designers an accurate map of the conformational switch that governs activity. More consequentially, diffusion-based and language-model-based protein design tools now allow researchers to specify a desired function—a binding interface, a cleavage site, a regulatory logic module—and generate amino acid sequences predicted to fold into structures that fulfill it. Rather than screening natural variants or making incremental mutations, designers can compose gasdermin-based molecules from the ground up, fusing pore-forming domains to sensor modules that respond to molecular features found only in infected cells.

The design logic described in the article follows a gating principle. An engineered construct remains inert until it encounters a virus-specific cue: a viral protease that cleaves a designed linker, a viral RNA or DNA species bound by an engineered sensor domain, or a host-state marker such as a receptor induced by interferon signaling. Only when the gate opens is the gasdermin N-terminal domain released or reconfigured to oligomerize at the membrane. In principle, such constructs could discriminate infected from uninfected tissue with a fidelity that natural inflammasome pathways, which respond to broad danger signals, cannot achieve. The article emphasizes that computational modeling of pore geometry, oligomerization energetics and membrane interactions is essential at every step, because even small deviations in the N-terminal domain can abolish pore formation or, conversely, produce toxic nonspecific membrane binding.

Experimental validation of AI-designed gasdermins, as discussed in the piece, proceeds through iterative cycles in which predicted structures are tested in liposome leakage assays, cell-culture infection models and, ultimately, animal studies. Key metrics include the tightness of the off state, the sensitivity and specificity of the trigger response, the efficiency of membrane pore formation and the immunological consequences of pyroptotic lysis in vivo. The authors highlight that design failures are informative: constructs that leak activity reveal the energetic margins of autoinhibition, while constructs that fail to activate expose weaknesses in sensor-linker coupling. Each cycle feeds data back into the design pipeline, a workflow that has already accelerated progress in other classes of engineered proteins, including designed cytokines, antibody mimetics and switchable cell-death regulators.

The therapeutic implications extend across antiviral medicine and beyond. A programmable gasdermin could, in principle, be delivered as a gene therapy or mRNA therapeutic to tissues vulnerable to a specific pathogen, standing ready to eliminate infected cells before viral spread becomes established. Such an approach would be particularly valuable against emerging viruses for which vaccines and antivirals lag behind outbreak speed, and against chronic infections where viral evasion of immune clearance is the central obstacle. The same design principles could be adapted to oncology, since many tumors evade pyroptosis by silencing gasdermin expression or downregulating inflammasome components, and engineered constructs triggered by tumor-specific proteases or neoantigens could restore an inflammatory form of cancer-cell death that promotes antigen release and immune priming. The article notes that the concept of AI-guided cell-death engineering generalizes: gasdermins are one member of a broader class of pore-forming effectors, including the immune proteins MLKL in necroptosis and the complement membrane-attack complex, whose activity might similarly be placed under synthetic control.

Substantial challenges temper the enthusiasm. Uncontrolled pyroptosis is dangerous: excessive gasdermin activation drives cytokine storms, tissue damage and septic shock, as demonstrated by the lethal inflammation observed when gasdermin pores open unchecked during severe infections. Any engineered system must therefore incorporate fail-safes, such as dependence on multiple simultaneous triggers, dose-limiting delivery strategies and pharmacological off switches. Immune responses against designed protein sequences pose another obstacle, as does the difficulty of achieving tissue-restricted expression. Off-target activation in bystander cells, even at low frequency, could produce disproportionate inflammation given the potency of the pore-forming mechanism. The authors stress that computational predictions, however accurate, must be paired with rigorous empirical safety testing across diverse cell types and inflammatory contexts before clinical translation can be contemplated.

Nevertheless, the trajectory is clear. The gasdermin system, once understood only as a blunt instrument of innate defense, is becoming a designable platform. Artificial intelligence supplies the structural insight and generative capacity to reprogram its trigger logic, its target selectivity and even its pore properties, while the underlying biology supplies a death mechanism that is fast, inflammatory and inherently immunogenic—qualities well suited to antiviral defense. The Cell Research article frames this convergence as the beginning of a programmable immunology, in which the executioners of cell death are no longer merely triggered by infection but are deliberately built to seek it out. If the engineering challenges of specificity, control and delivery can be met, AI-guided gasdermins may transform the treatment of viral disease from a defensive struggle into a precise, pre-emptive campaign against the cells that harbor the enemy.

Subject of Research: AI-guided engineering of gasdermin proteins to induce pyroptotic death of virus-infected cells

Article Title: Programmed to kill: AI-guided gasdermins eliminate virus-infected cells

Article References: Betrancourt, A., & Broz, P. (2026). Programmed to kill: AI-guided gasdermins eliminate virus-infected cells. Cell Research. https://doi.org/10.1038/s41422-026-01292-y

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01292-y

Keywords: gasdermin, pyroptosis, AI protein design, innate immunity, virus-infected cells, inflammasome, cell death, antiviral therapy, protein engineering, pore-forming proteins, Cell Research, immunotherapy

Long noncoding RNAs, typically defined as transcripts longer than two hundred nucleotides that are not translated into proteins, were once dismissed by many researchers as transcriptional noise. Early genome sequencing projects revealed that while only a small fraction of the human genome encodes proteins, the vast majority of it is transcribed into RNA. Skeptics argued that most of these transcripts were accidental byproducts of a cellular machinery that transcribes promiscuously. Over the past two decades, however, careful functional studies have dismantled that view. Individual long noncoding RNAs have been shown to sculpt chromatin, modulate the stability and translation of messenger RNAs, serve as scaffolds for multi-protein complexes, and act as molecular decoys that sequester transcription factors or microRNAs. Their regulatory reach extends across nearly every layer of gene expression, and their expression patterns are often exquisitely specific to particular cell types, developmental stages, and physiological conditions, including infection.

What makes the cross-kingdom framing particularly compelling is that long noncoding RNAs are not a peculiarity of animals. Plants produce them in abundance, and plant pathologists have documented RNA molecules that move from fungal pathogens into plant cells and vice versa. Small RNAs were the first cross-kingdom RNA travelers to be described in detail, with fungal pathogens such as Botrytis cinerea shown to deliver small RNAs into plant cells where they hijack the host’s own RNA interference machinery to suppress immune genes. Long noncoding RNAs now appear to participate in comparable exchanges, functioning both as sources of regulatory small RNAs and as independent effectors in their own right. In agricultural contexts, this discovery has opened an entirely new frontier: if pathogen RNAs silence crop immune genes, then engineered host RNAs might be deployed to silence essential pathogen genes, a strategy sometimes described as host-induced gene silencing.

In mammalian systems, the interplay between long noncoding RNAs and pathogens is equally rich. Upon infection, host cells reprogram their long noncoding RNA landscape on a massive scale. Interferon signaling, the centerpiece of antiviral immunity, induces a constellation of noncoding transcripts whose functions are only beginning to be mapped. Some of these RNAs amplify antiviral responses, acting as positive regulators that stabilize interferon-stimulated messenger RNAs or promote the signaling cascades triggered by pattern-recognition receptors. Others do the opposite, serving as brakes on inflammation that prevent immune damage to host tissues. Pathogens, in turn, have learned to manipulate this layer of regulation. Viruses encode their own noncoding RNAs and also reshape the abundance of host long noncoding RNAs, co-opting regulatory molecules to create a cellular environment favorable to viral replication, persistence, and escape from immune surveillance.

Bacterial pathogens add yet another dimension to the dialogue. Although bacteria do not possess the same RNA processing machinery as eukaryotes, they are masters of RNA regulation, using small RNAs and structured RNA elements to fine-tune gene expression in response to environmental cues. Emerging work suggests that bacterial RNAs can be released into host cells, whether through outer membrane vesicles, secretion systems, or the controlled lysis of bacterial cells, and that these molecules can modulate host signaling pathways. Conversely, host long noncoding RNAs influence the outcome of bacterial infection by regulating the expression of genes involved in innate immunity, inflammasome activation, autophagy, and cell death. Each of these pathways is a battleground, and RNA regulation sits at the heart of the fight.

The mechanistic versatility of long noncoding RNAs helps explain why they are such effective mediators of this dialogue. Unlike proteins, which must be synthesized, folded, and often trafficked through elaborate pathways, RNAs can be produced rapidly and can act through base-pairing interactions that are comparatively simple to predict and, at least in principle, to engineer. A single long noncoding RNA can interact with DNA, other RNAs, and proteins simultaneously, functioning as a hub that integrates multiple regulatory inputs. This multifunctionality means that a pathogen that targets one host long noncoding RNA can, in a single move, perturb an entire regulatory network. It also means that experimental perturbation of these RNAs, through antisense oligonucleotides, small interfering RNAs, or CRISPR-based approaches, can reveal network-level effects that single-gene knockout studies of proteins might miss.

Technological advances have driven much of the recent progress. Long-read sequencing technologies now allow full-length characterization of transcript isoforms, revealing complexity that short-read approaches obscured. Strand-specific and single-cell RNA sequencing methods have made it possible to profile the noncoding transcriptome of individual infected cells, exposing the heterogeneity of host responses within a tissue. Cross-kingdom RNA detection has benefited from computational pipelines designed to distinguish pathogen-derived reads from host transcripts, a nontrivial challenge given the low abundance of microbial RNAs within a sea of host RNA. Functional validation remains the rate-limiting step: assigning a concrete mechanism to a differentially expressed long noncoding RNA requires loss-of-function and gain-of-function experiments, mapping of interaction partners, and careful demonstration that observed effects are not artifacts of off-target perturbation. The field has matured considerably in its rigor, and the commentary in Cell Research reflects that maturation, emphasizing that the most convincing examples of cross-kingdom RNA communication are those in which the transferred RNA is detected in the recipient, its target is identified, and a functional consequence is demonstrated.

The translational implications are substantial. Host long noncoding RNAs that promote antiviral or antibacterial defense could serve as biomarkers that distinguish active infection from convalescence, or as predictors of disease severity. Therapeutically, RNA-based drugs have finally come of age: antisense oligonucleotides and small interfering RNA therapeutics have been approved for a range of conditions, and the mRNA vaccine success of the COVID-19 pandemic demonstrated that RNA delivery technologies can be scaled to global public health needs. Applying these tools to infection biology, whether by enhancing protective host noncoding RNAs or by directly silencing pathogen transcripts, is a logical next step. In agriculture, RNA-based crop protection strategies are already moving from the laboratory to the field, and a deeper understanding of cross-kingdom RNA exchange will inform both the design of such products and the assessment of their ecological effects on the wider microbiome.

Significant questions remain open. The mechanisms by which RNAs cross cellular boundaries, survive extracellular environments, and enter recipient cells are still incompletely understood, and the physiological relevance of some reported transfers continues to be debated. Dosage is a critical issue: RNA communication depends on molecules reaching functional concentrations in recipient cells, and measuring that accurately in vivo is technically demanding. Specificity is another challenge, since long noncoding RNAs often act at low levels through partial complementarity, raising the risk of unintended interactions when RNAs are manipulated therapeutically. Nonetheless, the conceptual shift is clear and consequential. Host and pathogen are no longer best understood as two organisms exchanging only molecular blows at the protein level; they are two transcriptomes in conversation, each reading and misreading the other’s RNA messages. The commentary’s central message, that long noncoding RNAs broaden the host–pathogen dialogue across kingdoms, captures a field in the midst of redefining itself, and it points toward a future in which the language of RNA becomes as central to infection biology as the language of proteins has always been.

Subject of Research: The role of long noncoding RNAs in cross-kingdom host–pathogen communication and infection biology.

Article Title: Long noncoding RNAs cross kingdoms to broaden host–pathogen dialogue

Article References: Halilovic, L., & Jin, H. (2026). Long noncoding RNAs cross kingdoms to broaden host–pathogen dialogue. Cell Research. https://doi.org/10.1038/s41422-026-01289-7

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01289-7

Keywords: long noncoding RNAs, host-pathogen interactions, cross-kingdom RNA, infection biology, antiviral immunity, gene regulation, RNA therapeutics, plant pathology, viral replication, interferon signaling, host-induced gene silencing, Cell Research

The central claim of the article, titled Metabolism licenses the senescence secretome, is that metabolic state functions as a gatekeeper determining which inflammatory and growth-promoting signals a senescent cell actually produces. In other words, two cells can be equally senescent by the classical criteria, showing stalled cell cycles, enlarged morphology and markers such as senescence-associated beta-galactosidase, yet produce dramatically different secretomes depending on how their metabolic machinery is configured. This reframing has significant consequences, because it suggests that targeting metabolism could offer a way to silence the harmful secretions of senescent cells without necessarily eliminating the cells themselves.

To understand why this idea matters, it helps to review what the senescence secretome actually contains. Depending on the cell type and the trigger, senescent cells can secrete pro-inflammatory cytokines such as interleukin-6 and interleukin-8, chemokines that recruit immune cells, matrix-remodeling enzymes including matrix metalloproteinases, growth factors that can drive neighboring cells to proliferate, and a variety of lipid mediators and extracellular vesicles carrying proteins and nucleic acids. In the short term, this signaling can be beneficial. It alerts the immune system to a potentially dangerous cell, promotes wound healing and contributes to tissue repair after injury. The problems arise when senescent cells accumulate with age or in diseased tissue, because their chronic secretory output then becomes a persistent source of low-grade inflammation, a phenomenon often described as inflammaging.

The traditional view of how the secretome is controlled has centered on DNA damage signaling. When cells experience telomere shortening, oxidative stress, oncogene activation or genotoxic drugs, they activate pathways involving the ATM and ATR kinases, which in turn engage the p53 and p21 axis and the p16INK4a and retinoblastoma pathway. These cascades enforce the cell-cycle arrest, and through the transcription factors NF-kappaB and C/EBP beta they also drive expression of many secreted factors. This DNA damage-centered model explains a great deal, but it leaves an important observation unexplained: the secretome varies enormously between contexts, and the same senescence trigger can produce very different inflammatory outputs in different metabolic environments.

The Cell Research perspective proposes that metabolism supplies the missing layer of regulation. Senescent cells undergo profound metabolic rewiring. They frequently display increased glycolysis, elevated mitochondrial oxidative phosphorylation, altered autophagic flux, changes in lipid metabolism and, in many cases, a shift toward biosynthetic programs that support their survival despite being unable to divide. Mitochondrial dysfunction is a particularly well-documented feature, and mitochondria that lose their integrity can release mitochondrial DNA and other damage-associated molecular patterns that amplify inflammatory signaling through innate immune sensors such as cGAS and Toll-like receptors. In this way, the metabolic state of the cell directly feeds the signaling circuits that assemble the secretome.

Several specific metabolic nodes illustrate the principle. The mevalonate pathway, best known for producing cholesterol, also generates isoprenoid intermediates required for the prenylation of small GTPases, and inhibition of this pathway with statins has been shown in multiple studies to blunt the secretion of inflammatory cytokines by senescent cells. Prostaglandin metabolism is another critical branch: the enzyme COX-2 and its downstream prostaglandin E2 production have been linked to the maintenance of the senescence program itself, and interfering with prostaglandin signaling can weaken both senescence and its secretory output. NAD metabolism, sirtuin activity, acetyl-CoA availability and histone acetylation states all influence how accessible the genes encoding secreted factors are to the transcriptional machinery. Even the availability of glucose and amino acids can shift the balance between a restrained and a fully inflammatory secretory phenotype.

This metabolic licensing concept also helps explain one of the most puzzling features of senescence biology: its heterogeneity. Single-cell analyses have revealed that senescent cells in the same tissue can express strikingly different sets of secreted factors, and that this diversity changes with age, tissue type and disease context. If the secretome were determined solely by the DNA damage response, one might expect more uniformity. But if the secretome is licensed by metabolism, then the local nutrient environment, oxygen tension, mitochondrial health and lipid availability of each cell would naturally produce a spectrum of secretory states. This heterogeneity is not noise; it is a direct readout of each cell’s metabolic circumstances, and it may explain why senescent cells can be reparative in one setting and destructive in another.

The therapeutic implications are considerable. Over the past decade, a class of drugs called senolytics has been developed to selectively kill senescent cells, and early clinical trials have reported encouraging results in conditions ranging from idiopathic pulmonary fibrosis to diabetic kidney disease. But clearing senescent cells entirely may not always be desirable, given their documented roles in wound healing, tissue regeneration and tumor suppression. An alternative strategy, sometimes called senomorphics, aims to reprogram senescent cells so that they retain their growth arrest and tumor-suppressive functions while losing their inflammatory secretions. The metabolic licensing framework provides a conceptual foundation for this approach: if metabolism licenses the secretome, then metabolic interventions, whether through statins, NAD-boosting compounds, mitochondrial modulators or dietary strategies, could in principle dial down the harmful components of the secretome while leaving the protective aspects of senescence intact.

The perspective also raises important questions for future research. Which metabolic enzymes are the critical licensing factors in vivo, and do they differ between tissues? How reversible is metabolic licensing, and can a senescent cell whose secretome has been silenced by metabolic intervention be pushed back into a benign state permanently, or only transiently? How do systemic factors such as diet, exercise and obesity, all of which reshape whole-body metabolism, modulate the secretory behavior of the senescent cells distributed throughout our tissues? And how do the metabolic states of senescent cells interact with the immune system, which must constantly decide whether to clear, tolerate or be activated by these cells? Answering these questions will require integrating metabolomics, single-cell transcriptomics and functional assays in physiologically relevant models, an effort the authors argue should now be a priority for the field.

What emerges from this analysis is a view of the senescent cell as a metabolically governed signaling hub rather than a passive casualty of damage. The DNA damage response may initiate senescence, but metabolism determines the character and intensity of the message the cell broadcasts to its neighbors. As the global population ages and age-related diseases place growing demands on health systems, the ability to modulate, rather than merely eliminate, senescent cells could become a cornerstone of geriatric medicine. The idea that metabolism licenses the senescence secretome offers both a unifying explanation for the heterogeneity that has long frustrated researchers and a practical roadmap for interventions that could preserve the benefits of cellular senescence while curbing its inflammatory costs. It is a reminder that in biology, as in economics, what a cell says depends heavily on the resources it has to spend.

Subject of Research: Metabolic regulation of the senescence-associated secretory phenotype in aging and disease

Article Title: Metabolism licenses the senescence secretome

Article References: Picallos Rabina, P., & Demaria, M. (2026). Metabolism licenses the senescence secretome. Cell Research. https://doi.org/10.1038/s41422-026-01295-9

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01295-9

Keywords: cellular senescence, senescence secretome, metabolism, inflammaging, mitochondrial dysfunction, senolytics, senomorphics, DNA damage response, aging, cytokines, NAD metabolism, Cell Research